Resistance to Lamivudine in HBV Egyptian Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

230 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-06-30

Study Completion Date

2013-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

On treatment parameters for Lamivudine resistance in HBV treated Egyptian patients

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primarily: To study the correlations between the following parameters in adult Egyptian patients with chronic viral hepatitis B before treatment:

* ALT.
* HBeAg.
* HBV-DNA by quantitative PCR.
* Biopsy (if possible). Secondarily: After receiving lamivudine therapy we will identify the impact of these parameters on viral breakthrough at 1 year of therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Hepatitis B Virus Treatment

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Hepatitis B virus Lamivudine Resistance to treatment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chronic HBV Egyptian patients

chronic HBV patients receiving Lamivudine therapy in hepatology clinic in the National Hepatology \& Tropical Medicine Research Institute in Egypt.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients \>18 years old
* Egyptian nationality
* Positive serology for HBsAg for more than 6 months
* Positive HBV viremia (above 2000IU/ml).
* Lamivudine monotherapy

Exclusion Criteria

* Anti-HBcIgM seropositivity
* Positive serology for HCV
* Positive serology for HDV
* Patients complicated with HCC

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Iman Fawzy Montasser

Lecturer of tropical medicine , Ain Shams university

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tropical medicine department

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HBV resistance

Identifier Type: -

Identifier Source: org_study_id